Table of Contents
Volume 2012, Article ID 867121, 10 pages
Review Article

Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Answers to Challenging “Real-World” Questions

1Serviço de Cardiologia, Hospital de Santa Cruz, Avenida Prof. Reinaldo dos Santos, 2790-134 Carnaxide, Portugal
2Serviço de Cardiologia, Hospital da Luz, Avenida Lusíada 100, 1500-650 Lisboa, Portugal
3CEDOC, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Rua da Junqueira 126, 1349-019 Lisboa, Portugal
4Serviço de Neurologia, Hospital Egas Moniz, 1349-019 Lisboa, Portugal
5Serviço de Medicina Interna, Hospital de São João, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
6Unidade de Saúde Familiar da Aguda, Avenida Padre Guilherme 21, 4405-010 Arcozelo, Portugal
7Hospital de Torres Vedras, Rua Dr. Ricardo Belo, 2560-324 Torres Vedras, Portugal

Received 15 December 2011; Revised 28 February 2012; Accepted 29 February 2012

Academic Editor: Edith Nutescu

Copyright © 2012 Jorge Ferreira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Dabigatran etexilate is a novel, oral, reversible, direct thrombin inhibitor that constitutes a major breakthrough for stroke prevention in patients with nonvalvular atrial fibrillation (AF). Dabigatran was the first new oral anticoagulant approved in Europe and became available in Portugal, for stroke prevention in nonvalvular AF, earlier than in most European countries. This paper is the joint effort of a panel of experts from different specialties and provides information on the use of dabigatran, in anticipation of the challenges that will come with increased usage.